TransMedics Q1 revenue rises 21% to $173.9 million; net income falls to $7.3 million
TransMedics reported first quarter 2026 revenue of $173.9 million, up 21% from a year earlier, but net income fell to $7.3 million, or $0.20 per diluted share, from $25.7 million, or $0.70 per share, in the first quarter of 2025. The company reiterated its full year 2026 revenue guidance of $727 million to $757 million, which it said represents 20% to 25% growth.
Key points
- Revenue of $173.9 million for the quarter ended March 31, 2026, up 21% from $143.5 million a year earlier
- Net income of $7.3 million, or $0.20 per diluted share, versus $25.7 million, or $0.70, in the prior-year quarter; gross margin was 58% compared with 61%
- Adjusted net income of $10.9 million, or $0.30 per diluted share, a non-GAAP measure; cash was $461.7 million as of March 31, 2026
- Full year 2026 revenue guidance of $727 million to $757 million was reiterated, not changed
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.